Evidence map›Paper›PMID 37133395›Full record

ArticleMicrobiology spectrum2023

Clinical, Bacteriological, and Genetic Characterization of Bone and Joint Infections Involving Linezolid-Resistant Staphylococcus epidermidis: a Retrospective Multicenter Study in French Reference Centers.

François Coustillères, Victor Renault, Stéphane Corvec, Céline Dupieux, Patricia Martins Simões, Marie Frédérique Lartigue, Chloé Plouzeau-Jayle, Didier Tande, Claudie Lamoureux, Carole Lemarié and 5 more

Open access · goldAbstract readMulticenter Study
In one paragraph

Article in Microbiology spectrum, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 11 citations in OpenAlex.

  1. How long should we keep clinical isolates involved in bone and joint infections in microbiology laboratories?European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026
    Review
  2. Article
  3. Molecular basis of linezolid resistance inAntimicrobial agents and chemotherapy · 2026
    Article
  4. Delafloxacin: what does a new fluoroquinolone offer?Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2026
    Review
  5. Dalbavancin-resistantJAC-antimicrobial resistance · 2024
    Article
  6. Article
  7. Investigation of a linezolid-resistantFrontiers in microbiology · 2024
    Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 6 institutions in 1 country.

François Coustillères *Service des Maladies Infectieuses, Centre Hospitalier Régional Universitaire, Centre Régional de Référence pour la prise en charge des IOA complexes (CRIOGO), Tours, France.
Victor Renault *Service de Bactériologie et des Contrôles microbiologiques, Hôtel-Dieu, Centre Hospitalier Universitaire, Centre Régional de Référence pour la prise en charge des IOA complexes (CRIOGO), Nantes, France.
Stéphane CorvecService de Bactériologie et des Contrôles microbiologiques, Hôtel-Dieu, Centre Hospitalier Universitaire, Centre Régional de Référence pour la prise en charge des IOA complexes (CRIOGO), Nantes, France.ORCID 0000-0003-3176-8111
Céline DupieuxHospices Civils de Lyon, Institut des Agents Infectieux, Service de Bactériologie, Centre National de Référence des Staphylocoques, Centre Régional de Référence pour la prise en charge des IOA complexes (CRIOAC Lyon), France.
Patricia Martins SimõesHospices Civils de Lyon, Institut des Agents Infectieux, Service de Bactériologie, Centre National de Référence des Staphylocoques, Centre Régional de Référence pour la prise en charge des IOA complexes (CRIOAC Lyon), France.
Marie Frédérique LartigueService de Bactériologie et d'Hygiène, Centre Hospitalier Régional Universitaire, Centre Régional de Référence pour la prise en charge des IOA complexes (CRIOGO), Tours, France.
Chloé Plouzeau-JayleService de Bactériologie et d'Hygiène, Centre Hospitalier Universitaire, Centre Régional de Référence pour la prise en charge des IOA complexes (CRIOGO), Poitiers, France.
Didier TandeService de Bactériologie et d'Hygiène, Centre Hospitalier Universitaire, Centre Régional de Référence pour la prise en charge des IOA complexes (CRIOGO), Brest, France.
Claudie LamoureuxService de Bactériologie et d'Hygiène, Centre Hospitalier Universitaire, Centre Régional de Référence pour la prise en charge des IOA complexes (CRIOGO), Brest, France.
Carole LemariéService de Bactériologie et d'Hygiène, Centre Hospitalier Universitaire, Centre Régional de Référence pour la prise en charge des IOA complexes (CRIOGO), Angers, France.
Rachel ChenouardService de Bactériologie et d'Hygiène, Centre Hospitalier Universitaire, Centre Régional de Référence pour la prise en charge des IOA complexes (CRIOGO), Angers, France.
Frédéric LaurentHospices Civils de Lyon, Institut des Agents Infectieux, Service de Bactériologie, Centre National de Référence des Staphylocoques, Centre Régional de Référence pour la prise en charge des IOA complexes (CRIOAC Lyon), France.
Adrien LemaignenService des Maladies Infectieuses, Centre Hospitalier Régional Universitaire, Centre Régional de Référence pour la prise en charge des IOA complexes (CRIOGO), Tours, France.
Pascale BémerService de Bactériologie et des Contrôles microbiologiques, Hôtel-Dieu, Centre Hospitalier Universitaire, Centre Régional de Référence pour la prise en charge des IOA complexes (CRIOGO), Nantes, France.ORCID 0000-0001-5892-2946
CRIOGO (Centre de Référence des Infections Ostéo-articulaires du Grand Ouest) Study Team
Centre Hospitalier Universitaire de Tours · FRCentre Hospitalier Universitaire de Nantes · FRCentre Hospitalier Universitaire d'Angers · FRHospices Civils de Lyon · FRCentre Hospitalier Régional Universitaire de Brest · FRCentre Hospitalier Universitaire de Poitiers · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The choice of the best probabilistic postoperative antibiotics in bone and joint infections (BJIs) is still challenging. Since the implementation of protocolized postoperative linezolid in six French referral centers, linezolid-resistant multidrug-resistant Staphylococcus epidermidis (LR-MDRSE) strains were isolated in patients with BJI. We aimed here to describe clinical, microbiological, and molecular patterns associated with these strains. All patients with at least one intraoperative specimen positive for LR-MDRSE between 2015 and 2020 were included in this retrospective multicenter study. Clinical presentation, management, and outcome were described. LR-MDRSE strains were investigated by MIC determination for linezolid and other anti-MRSA antibiotics, characterization of genetic determinants of resistance, and phylogenetic analysis. Forty-six patients (colonization

Indexed as

DaptomycinMethicillin-Resistant Staphylococcus aureusOxazolidinonesStaphylococcal InfectionsAnti-Bacterial AgentsCeftarolineCephalosporinsClindamycinDrug Resistance, BacterialGentamicinsHumansInterleukin-1 Receptor-Like 1 ProteinLinezolidMicrobial Sensitivity TestsOfloxacinPhylogenyAnti-Bacterial AgentsCeftarolineceftobiproleCephalosporinsClindamycinDaptomycinGentamicinsInterleukin-1 Receptor-Like 1 ProteinLinezolidOfloxacinOxazolidinonesRifampinRNA, Ribosomal, 23Sbone and joint infectionslinezolid exposurelinezolid-resistant multidrug-resistant Staphylococcus epidermidismultiresistanceresistance to linezolidesequence type ST2Staphylococcus epidermidis

Identifiers

PMID37133395
PMCPMC10269892
OpenAlexW4367834226

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.